<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00132678</url>
  </required_header>
  <id_info>
    <org_study_id>CR002278</org_study_id>
    <secondary_id>RISBIM3003</secondary_id>
    <nct_id>NCT00132678</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Explore the Efficacy and Safety of Risperidone Long-acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar 1 Disorder, With Open-label Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if risperidone is effective and safe in the
      prevention of mood episodes in patients with bipolar 1 disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RISPERDAL CONSTA (risperidone long-acting injection) may provide substantial improvement, by
      reducing patient non-compliance, in the long-term treatment of bipolar I disorder. This is a
      randomized (patients are assigned different treatments based on chance), double-blind,
      (neither the patient nor the physician knows whether drug or placebo is being taken, or at
      what dosage) placebo-controlled study to explore the safety and effectiveness of RISPERDAL
      CONSTA in the prevention of mood episodes in patients with bipolar 1 disorder. This study
      includes 5 periods: a screening period lasting up to 1 week; an open-label RISPERDAL (oral
      risperidone) treatment period lasting 3 weeks; an open-label RISPERDAL CONSTA stabilization
      period lasting 26 weeks; a double-blind period lasting up to 24 months; and an open-label
      extension with RISPERDAL CONSTA lasting 8 weeks. Efficacy will be assessed using the Young
      Mania Rating Scale (YMRS), Montgomery-Åsberg Depression Rating Scale (MADRS), Clinical Global
      Impressions - Severity (CGI-S) scale, Medical Outcomes Study Short Form 36 (SF-36), and the
      Personal and Social Performance (PSP) scale. Safety will be evaluated throughout the study
      and includes assessment of adverse events, clinical laboratory tests (including hematology,
      serum chemistry, blood glucose/lipid profile, prolactin, and urinalysis); electrocardiograms
      (ECGs), vital signs (pulse and blood pressure), physical examination, body mass index (BMI),
      and the Extrapyramidal Symptom Rating Scale (ESRS). Oral risperidone (flexible dosage) 1 to 6
      mg/day for the first 3 weeks. Risperidone LAI i.m. injections (12.5mg, 25 mg, 37.5 mg, or 50
      mg) given every 2 weeks for up to approximately 2.6 years (only 6 months for patients
      receiving placebo during DB-period)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Had a Mood Relapse.</measure>
    <time_frame>24 months</time_frame>
    <description>Mood Relapse was defined as:
The subject met DSM-IV criteria for a manic, hypomanic, mixed, or depressive episode; or, the subject needed treatment intervention with any mood stabilizer, antipsychotic medication (other than study drug), benzodiazepine (beyond the dosage allowed), or antidepressant medication; or the subject required hospitalization for any bipolar mood episode; or the subject had a YMRS or MADRS score &gt;12 or a CGI-S score &gt;4; or a dose increase, or supplementation with oral risperidone or another antipsychotic or mood stabilizer, was needed in the opinion of the investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Young Mania Rating Scale (YMRS) Scores.</measure>
    <time_frame>Baseline and Endpoint (last observation carried forward) of 24 month Double-Blind Period IV</time_frame>
    <description>Measure of mania; score range 0 to 60 (lower score = less severity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Montgomery-Åsberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Baseline and Endpoint (last observation carried forward) of 24 month Double-Blind Period IV</time_frame>
    <description>Measure of depression; score range 0 to 60 (lower score = less severity)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">559</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Risperdal Consta 12.5 25 37.5 or 50mg intramuscular (IM) injection every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Matching placebo intramuscular (IM) injection every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperdal Consta</intervention_name>
    <description>12.5, 25, 37.5 or 50mg intramuscular (IM) injection every 2 weeks</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo intramuscular (IM) injection every 2 weeks</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of bipolar 1 disorder, currently experiencing a mixed or manic episode or
             stable

          -  Two or more bipolar mood episodes in the last 2 years excluding current episode

          -  Negative pregnancy test

        Exclusion Criteria:

          -  History of &gt; than 4 mood episodes a year during the last two years

          -  patients experiencing a depressive episode

          -  History of antisocial or borderline personality illness

          -  Has unstable or serious general medical illness

          -  Has received medications disallowed by study criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L. C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>National City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clementon</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyndhurst</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Desoto</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neunkirchen</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manipal</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johor Bahru</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kota Bharu</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Choroszcz N/A</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Swiecie Poland</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tuszyn N/A</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lipetsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow N/A</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow Region</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow Russia</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nizny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Samara N/A</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saratov N/A</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg N/A</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St-Petresburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rimavska Sobota</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tao-Yuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glevakha</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lvov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Simferopol</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>India</country>
    <country>Malaysia</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&amp;studyid=27&amp;filename=CR002278_CSR.pdf</url>
    <description>A study of the efficacy and safety of injectable risperidone in the prevention of bipolar mood episodes</description>
  </link>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>August 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2005</study_first_posted>
  <results_first_submitted>October 24, 2008</results_first_submitted>
  <results_first_submitted_qc>January 26, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 27, 2009</results_first_posted>
  <last_update_submitted>July 23, 2013</last_update_submitted>
  <last_update_submitted_qc>July 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mood episodes</keyword>
  <keyword>Bipolar 1 disorder</keyword>
  <keyword>Intramuscular Injectable</keyword>
  <keyword>risperidone</keyword>
  <keyword>safety and efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 559 (440 + 119) subjects received at least one dose of study drug. A total of 440 subjects (acute episode or stable on other antipsychotic) entered period II, 382 subjects completed and entered period III. An additional 119 subjects (stable on risperidone) entered period III directly. Overall 501 (382 + 119) subjects entered period III.</recruitment_details>
      <pre_assignment_details>Subjects with an acute episode or who were stable on another antipsychotic entered Period II; Period II responders entered Period III. Subjects stable on RIS at screening entered Period III directly. Subjects who maintained response and had a stable dose of RIS LAI for the last 8 weeks of Period III were randomized to RIS LAI or placebo(Period IV).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RISPERDAL CONSTA</title>
          <description>risperidone long acting injectable (RIS LAI) 12.5, 25, 37.5 or 50 mg intramuscular (IM) injection every 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>intramuscular (IM) injection every 2 weeks</description>
        </group>
        <group group_id="P3">
          <title>Open-Label Oral Risperidone</title>
          <description>(flexible dosage) 1 to 6 mg/day for the first 3 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period II (Open-Label Oral Risperidone)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="440"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="382"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="58"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non responder</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible to continue trial</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period III (Open-Label Stabilization)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="501"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="303"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="198"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non responder</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible to continue trial</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject non-compliant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period IV (Double-Blind Treatment)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="154"/>
                <participants group_id="P2" count="149"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="109"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible to continue the trial</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Non-compliant</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RISPERDAL CONSTA</title>
          <description>risperidone long acting injectable (RIS LAI) 12.5, 25, 37.5 or 50 mg IM injection every 2 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>IM injection every 2 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="154"/>
            <count group_id="B2" value="149"/>
            <count group_id="B3" value="303"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.1" spread="11.81"/>
                    <measurement group_id="B2" value="39.2" spread="12.40"/>
                    <measurement group_id="B3" value="39.2" spread="12.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Had a Mood Relapse.</title>
        <description>Mood Relapse was defined as:
The subject met DSM-IV criteria for a manic, hypomanic, mixed, or depressive episode; or, the subject needed treatment intervention with any mood stabilizer, antipsychotic medication (other than study drug), benzodiazepine (beyond the dosage allowed), or antidepressant medication; or the subject required hospitalization for any bipolar mood episode; or the subject had a YMRS or MADRS score &gt;12 or a CGI-S score &gt;4; or a dose increase, or supplementation with oral risperidone or another antipsychotic or mood stabilizer, was needed in the opinion of the investigator.</description>
        <time_frame>24 months</time_frame>
        <population>Intention to treat. 28 subjects from a Good Clinical Practice noncompliant site and 1 site with alleged research misconduct were excluded from efficacy analyses. The median (interquartile range) for time to relapse (d): Risperdal Consta: NA (173, NA) &amp; Placebo: 219 (82, NA) [NA = not available; Risperdal Consta relapse percent &lt; 50% &amp; Placebo &lt;75%]</population>
        <group_list>
          <group group_id="O1">
            <title>RISPERDAL CONSTA</title>
            <description>risperidone long acting injectable (RIS LAI) 12.5, 25, 37.5 or 50 mg IM injection every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>IM injection every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had a Mood Relapse.</title>
          <description>Mood Relapse was defined as:
The subject met DSM-IV criteria for a manic, hypomanic, mixed, or depressive episode; or, the subject needed treatment intervention with any mood stabilizer, antipsychotic medication (other than study drug), benzodiazepine (beyond the dosage allowed), or antidepressant medication; or the subject required hospitalization for any bipolar mood episode; or the subject had a YMRS or MADRS score &gt;12 or a CGI-S score &gt;4; or a dose increase, or supplementation with oral risperidone or another antipsychotic or mood stabilizer, was needed in the opinion of the investigator.</description>
          <population>Intention to treat. 28 subjects from a Good Clinical Practice noncompliant site and 1 site with alleged research misconduct were excluded from efficacy analyses. The median (interquartile range) for time to relapse (d): Risperdal Consta: NA (173, NA) &amp; Placebo: 219 (82, NA) [NA = not available; Risperdal Consta relapse percent &lt; 50% &amp; Placebo &lt;75%]</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Relapsed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" lower_limit="173"/>
                    <measurement group_id="O2" value="76" lower_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Relapsed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Log Rank</method>
            <method_desc>Adjusting for country</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
            <estimate_desc>RISPERDAL CONSTA hazard in numerator, placebo hazard in denominator.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Young Mania Rating Scale (YMRS) Scores.</title>
        <description>Measure of mania; score range 0 to 60 (lower score = less severity)</description>
        <time_frame>Baseline and Endpoint (last observation carried forward) of 24 month Double-Blind Period IV</time_frame>
        <population>Restricted to subjects with paired baseline and visit endpoint (Period IV) data only. Endpoint is the patient’s last nonmissing, postbaseline value in Period IV (last observation carried forward technique)</population>
        <group_list>
          <group group_id="O1">
            <title>RISPERDAL CONSTA</title>
            <description>risperidone long acting injectable (RIS LAI) 12.5, 25, 37.5 or 50 mg IM injection every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>IM injection every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Young Mania Rating Scale (YMRS) Scores.</title>
          <description>Measure of mania; score range 0 to 60 (lower score = less severity)</description>
          <population>Restricted to subjects with paired baseline and visit endpoint (Period IV) data only. Endpoint is the patient’s last nonmissing, postbaseline value in Period IV (last observation carried forward technique)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="7.34"/>
                    <measurement group_id="O2" value="9.1" spread="10.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with factors for treatment and country and double-blind baseline value as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.08</ci_lower_limit>
            <ci_upper_limit>-3.79</ci_upper_limit>
            <estimate_desc>Change in RISPERDAL CONSTA arm minus change in placebo arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Montgomery-Åsberg Depression Rating Scale (MADRS)</title>
        <description>Measure of depression; score range 0 to 60 (lower score = less severity)</description>
        <time_frame>Baseline and Endpoint (last observation carried forward) of 24 month Double-Blind Period IV</time_frame>
        <population>Restricted to subjects with paired baseline and visit endpoint (Period IV) data only. Endpoint is the patient’s last nonmissing, postbaseline value in Period IV (last observation carried forward technique)</population>
        <group_list>
          <group group_id="O1">
            <title>RISPERDAL CONSTA</title>
            <description>risperidone long acting injectable (RIS LAI) 12.5, 25, 37.5 or 50 mg IM injection every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>IM injection every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Montgomery-Åsberg Depression Rating Scale (MADRS)</title>
          <description>Measure of depression; score range 0 to 60 (lower score = less severity)</description>
          <population>Restricted to subjects with paired baseline and visit endpoint (Period IV) data only. Endpoint is the patient’s last nonmissing, postbaseline value in Period IV (last observation carried forward technique)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="6.66"/>
                    <measurement group_id="O2" value="4.9" spread="8.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with factors for treatment and country and double-blind baseline value as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.75</ci_lower_limit>
            <ci_upper_limit>-0.32</ci_upper_limit>
            <estimate_desc>Change in RISPERDAL CONSTA arm minus change in placebo arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>RISPERDAL CONSTA</title>
          <description>Double-blind Period IV. Risperidone long acting injectable (RIS LAI) 12.5, 25, 37.5 or 50 mg intramuscular (IM) injection every 2 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Double-blind Period IV. Intramuscular (IM) injection every 2 weeks</description>
        </group>
        <group group_id="E3">
          <title>Open-Label Oral Risperidone</title>
          <description>Open-label Period II. Flexible dosage. 1 to 6 mg/day for the first 3 weeks</description>
        </group>
        <group group_id="E4">
          <title>Open Label RISPERDAL CONSTA</title>
          <description>Open-label Period III. Risperidone long acting injectable (RIS LAI) 12.5, 25, 37.5 or 50 mg intramuscular (IM) injection every 2 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Accidental death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Chemical poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Hepatic rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Hallucination, auditory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="155" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Sommolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Number affected in Open-Label RISPERDAL CONSTA does not include the event of insomnia in the Serious Adverse Event table.</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="66" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <description>Number affected in Open-Label RISPERDAL CONSTA does not include the event of anxiety in the Serious Adverse Event table.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Research</name_or_title>
      <organization>Johnson &amp; Johnson Pharmaceutical Research and Development</organization>
      <phone>609 730-4576</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

